Latest Healthcare Research Report

Researchmoz added Most up-to-date research on "PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The base-year market leader in the US is Roche/Novartis Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face st...

Researchmoz added Most up-to-date research on "PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The 2012 base-year market sales of products for MCD in France were around $153m. As in the global market, this growth will be fueled by the dramatic increase in prevalence and diagnosis, as well...

ResearchMoz presents this most up-to-date research on PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The currently marketed product with the highest growth rate over the forecast period will be Regeneron/Bayers Eylea. Even though the drug is still in the pipeline for DME, it is being used off-label already. Its usage will drastically incre...

Researchmoz added Most up-to-date research on "PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The uptake of drugs receiving additional approval for diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further drive sales in the MCD market. A dip in sales in the diabetic neur...

ResearchMoz presents this most up-to-date research on PharmaPoint: Microvascular Complications of Diabetes - Spain Drug Forecast and Market Analysis to 2022. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The uptake of drugs receiving additional approval for diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further drive sales in the MCD market. A dip in sales in the diabetic neuropathy market will happen from mid-2014 due to ...

ResearchMoz presents this most up-to-date research on PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022. The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The currently marketed product with the highest growth rate over the forecast period will be Regeneron/Bayers Eylea. Despite the drug still being in the pipeline for DME, it is being used off-label already. Its usage will drastically increase up...